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Abstract: Acute coronary syndromes (ACS) are the leading cause of mortality and one of the 
main reasons for hospital admissions in the developed nations. Due to high rates of mortality 
and reinfarction, ACS represent a major public health concern. Platelets play a central role 
in atherothrombosis, the main pathologic substrate in ACS. Sufficient inhibition of platelet 
aggregation is therefore one of the key targets in the treatment of ACS. Blockade of the 
P2Y12 subtype of adenosine diphosphate (ADP) receptor on platelet cell membranes has been 
established as a key mechanism of platelet inhibition. Clopidogrel, an ADP receptor antagonist 
and a second-generation thienopyridine, has been demonstrated to be of clinical benefit in patients 
with ACS when added to aspirin. A delayed onset of action due to two-step conversion to the 
active metabolite, irreversible binding to P2Y12 receptors, and broad interindividual variability 
in levels of platelet response are the main limitations of clopidogrel. Prasugrel, a novel third-
generation thienopyridine, provides faster and stronger inhibition of platelet aggregation than 
clopigodrel. However, like the active metabolite of clopidogrel, prasugrel binds irreversibly to 
the P2Y12 ADP receptor site, causing inhibition of platelet aggregation for the life of the platelet. 
Although in a randomized, double-blind trial prasugrel demonstrated superiority for multiple 
cardiovascular endpoints compared with standard-dose clopidogrel, it was also associated with 
an increased bleeding risk, including fatal bleeding. This review discusses the optimal antiplatelet 
regimens for management of patients with ACS, with special focus on ticagrelor, the first oral 
agent in a new chemical class of nonthienopyridine antiplatelet agents termed cyclopentyl-
triazolo-pyrimidines. Faster and greater platelet inhibition than clopidogrel, quick recovery of 
platelet function, and high efficacy regardless of clopidogrel response status, are the obvious 
advantages of ticagrelor as compared with thienopyridines. The prospective, randomized Platelet 
Inhibition and Patient Outcomes trial has established the clinical utility, enhanced efficacy, and 
similar safety of ticagrelor as compared with clopidogrel in a wide range of patients with ACS 
managed with contemporary antithrombotic therapies and invasive strategies when indicated. 
Dyspnea, ventricular pauses $3 seconds, and elevation of serum creatinine and uric acid are 
the most common known adverse effects associated with ticagrelor, and require further com-
prehensive assessment.
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Introduction
Acute coronary syndromes (ACS) are the leading cause of mortality and one of the 
main reasons for hospital admissions in the developed nations.1 Improvement of out-
comes in patients with ACS is therefore a major health care task.
Platelets play a central role in atherothrombosis, the main pathologic substrate in 
ACS.2,3 Several platelet membrane receptors (Figure 1) bind with extracellular factors Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in response to platelet activation, resulting in platelet adhesion 
and aggregation. Sufficient platelet inhibition is crucial to 
prevent formation of thrombus and related ischemic events.
Aspirin and thienopyridines have been demonstrated to 
be of clinical benefit in patients with ACS, and are currently 
recommended with a Class I level of evidence by the guidelines 
issued by the American Heart Association, American College 
of Cardiology, and European Society of Cardiology.4,5
Aspirin and thienopyridines  
in ACS treatment
By inhibition of cyclo-oxygenase, the enzyme that metabo-
lizes arachidonic acid, a fatty acid from the cell membrane, 
aspirin irreversibly blocks the formation of thromboxane A2 
in platelets, providing an inhibitory effect on platelet aggre-
gation. In the second International Study of Infarct Survival 
(ISIS-2) in patients with ST segment elevation myocardial 
infarction (STEMI), the use of aspirin as opposed to placebo 
was associated with a highly significant reduction in vascular 
mortality (9.4% versus 11.8%, P , 0.00001) along with sig-
nificant reduction in rates of reinfarction (1.0% versus 2.0%) 
and nonfatal stroke (0.3% versus 0.6%) at five weeks.6
Blockade of the P2Y12 subtype of adenosine diphos-
phate (ADP) receptor on platelet cell membranes (Figure 1) 
has been established as another key mechanism of platelet 
inhibition. Clopidogrel bisulfate (Bristol-Myers Squibb, 
Princeton, NJ; sanofi-aventis, Bridgewater, NJ), an ADP 
receptor antagonist and a second-generation thienopyri-
dine, is converted from the inactive parent compound to the 
active metabolite via the cytochrome P system in a two-step 
process. The active metabolite of clopidogrel binds to the 
P2Y12 ADP receptor site causing irreversible inhibition of 
platelet aggregation for the life of the platelet. The clinical 
benefits associated with inhibiting the ADP- P2Y12 receptor 
pathway of platelet activation with clopidogrel in addition 
to aspirin were demonstrated in the randomized, placebo-
controlled, double-blind Clopidogrel in Unstable Angina 
to Prevent Recurrent Events (CURE) trial.7 Both 12-month 
primary endpoints (a composite of death from cardiovascular 
causes, nonfatal myocardial infarction [MI]), or stroke and 
a composite of death from cardiovascular causes, nonfatal 
MI, stroke, or refractory ischemia) occurred significantly 
(P , 0.001) less frequently in the clopidogrel group than 
in the placebo group (9.3% versus 11.4% and 16.5% versus 
18.8%, respectively). Among patients undergoing percuta-
neous coronary intervention (PCI) in the CURE trial, there 
was a significant 31% reduction of cardiovascular death or 
MI at one year (8.8% versus 12.6%, P = 0.002; Figure 2). 
However, there was a 1% excess risk of major bleeding in the 
clopidogrel group compared with the placebo group (3.7% 
versus 2.7%, P = 0.001).
Prasugrel (Daiichi Sankyo Company, Ltd., Parsippany, 
NJ; Eli Lilly, Indianapolis, IN), a novel third-generation 
thienopyridine, like clopidogrel needs cytochrome-dependent 
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Figure 1 Schema of platelet receptor-ligand interactions. Copyright © 2009. Adapted with permission from Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Platelet 
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metabolism to gain activity, but requires a single-step for 
activation, providing stronger inhibition of platelet aggregation 
than clopidogrel. In the randomized, double-blind, two-phase, 
crossover Prasugrel in Comparison to Clopidogrel for Inhi-
bition of Platelet Activation and Aggregation-Thrombolysis 
in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) study, 
in a total of 201 patients undergoing planned PCI, loading 
with 60 mg prasugrel as opposed to 600 mg clopidogrel 
resulted in faster and greater inhibition of platelet aggrega-
tion with 20 µmol/L ADP at six hours (74.8% ± 13.0% versus 
31.8% ± 21.1%, respectively, P , 0.0001).8 This difference 
was evident as early as at 30 minutes (30.8% ± 29.0% for 
prasugrel versus 4.9% ± 13.2% for clopidogrel, P , 0.001). 
Similarly, during the maintenance dose phase, inhibition 
of platelet aggregation after 14 ± 2 days of treatment was 
higher in patients receiving prasugrel 10 mg/day than those 
receiving clopidogrel 150 mg/day (61.3% ± 17.8% versus 
46.1% ± 21.3%, P , 0.0001). In the randomized, double-
blind Phase III Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, 
involving patients with ACS scheduled for PCI, at a median 
follow-up of 14.5 months prasugrel therapy was associated 
with significantly reduced rates of the primary efficacy end-
point of cardiovascular death, nonfatal MI, and nonfatal stroke 
(9.9% versus 12.1%, P , 0.001, Figure 3).9
Main limitations of thienopyridines
Clopidogrel as an antiplatelet agent has several principal 
drawbacks. The first limitation is related to the metabolism 
of clopidogrel, which is a prodrug requiring two-step activa-
tion involving several hepatic cytochrome P isoenzymes to 
convert to the active metabolite. This results in a delayed 
onset of action (6–8 hours after a 300 mg loading dose) and 
potentially increases the risk of ischemic events especially 
in the scenario of urgent coronary intervention. Doubling of 
the loading dose from 300 mg to 600 mg with a subsequent 
increase in the maintenance dose from 75 mg to 150 mg for 
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Figure 2 Cumulative hazard ratios for the primary endpoint of cardiovascular death, nonfatal myocardial infarction, or stroke during the 12 months of the CURE study. 
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seven days, in the recently reported randomized Clopidogrel 
Optimal Loading Dose Usage to Reduce Recurrent Events/
Optimal Antiplatelet Strategy for Interventions (CURRENT 
OASIS-7) trial in an ACS population (Figure 4) had no signifi-
cant effect on the primary endpoint of cardiovascular death, MI, 
or stroke at 30 days (4.2% in patients on the high dose versus 
4.4% in patients on the standard dose; hazard ratio [HR] 0.95, 
95% confidence interval [CI]: 0.84–1.07).10 However, among 
patients managed with PCI within 24 hours (approximately two 
thirds of the study patients), high-dose clopidogrel yielded a 
significant 15% reduction in the composite of cardiovascular, 
death, MI, or stroke (3.9% versus 4.5%, HR 0.85, 95% CI: 
0.74–0.99) that was driven mainly by significantly lower rates 
of MI in the high-dose clopidogrel group (2.0% versus 2.6%, 
HR 0.78, 95% CI: 0.64–0.95). There was also a significant 42% 
reduction in the risk of the key secondary endpoint of definite 
stent thrombosis in the high-dose clopidogrel group (0.7% 
versus 1.2%, HR 0.58, 95% CI: 0.42–0.79). However, reduc-
tion in the rates of ischemic endpoints was offset by higher 
rates of major bleeding with the higher clopidogrel dose both 
in the entire study population (2.5% versus 2.0%; HR 1.25, 
95% CI: 1.05–1.47) and in the PCI population (1.6% versus 
1.1%; HR 1.44, 95% CI: 1.11–1.86).
The second limitation of clopidogrel is related to its 
irreversible binding to P2Y12 receptors, leading to a gradual 
recovery of platelet function after drug withdrawal. This 
places patients who need urgent surgical revascularization at 
increased risk of bleeding within 5–7 days after cessation of 
clopidogrel. In the CURE study, among patients undergoing 
coronary artery bypass grafting (CABG), bleeding tended 
to be more common if CABG was performed within five 
days of clopidogrel administration (8.5% with clopidogrel 
versus 5.7% with placebo, P = 0.07), compared with longer 
than five days (4.4% versus 5.3%, P = 0.53).11 Furthermore, 
in a prospective study of 224 consecutive patients under-
going nonemergent first-time CABG, patients with versus 
without preoperative clopidogrel exposure within seven 
days had greater 24-hour mean chest tube output (1224 mL 
versus 840 mL, P = 0.001), were less frequently extubated 
within eight hours (54.2% versus 75.8%, P = 0.002), 
required more frequent transfusions of packed red blood 
cells (2.51 units versus 1.74 units, P = 0.04), platelets 
(0.86 units versus 0.24 units, P = 0.001), and fresh frozen 
plasma (0.68 units versus 0.24 units, P = 0.02), and had 
significantly higher rates of reoperation for bleeding (6.8% 
versus 0.6%, P = 0.018).12
0
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The broad interindividual variability in levels of platelet 
inhibition achieved with clopidogrel is the third limitation 
of clopidogrel as an antiplatelet agent. Clopidogrel results 
in only 30% to 40% mean inhibition of platelet aggregation 
response to ADP, with up to one third of patients having 
inadequate platelet inactivation (“nonresponders”).13 This 
has particular significance given that clopidogrel resistance 
correlates with higher rates of ischemic events.14
Within the last few years, bleeding is gaining recognition 
as the most common complication in patients with ACS.15 
Because hemorrhagic events confer an unfavorable prognosis 
in patients with ACS,16–18 bleeding and ways of preventing it 
assume particular importance. Increased risk of hemorrhagic 
events is the main disadvantage of prasugrel as compared with 
clopidogrel. In the randomized, double-blind TRITON-TIMI 38 
trial, treatment with prasugrel was associated with an increased 
rate of non-CABG-related major TIMI bleeding (2.4% versus 
1.8%, P = 0.03), including life-threatening bleeding (1.4% 
versus 0.9%, P = 0.01) and fatal bleeding (0.45% versus 0.15%, 
P = 0.002).9 Besides, CABG-related major TIMI bleeding 
occurred more frequently with prasugrel (13.4% versus 3.2%, 
P , 0.001), including two cases of fatal bleeding in the pra-
sugrel group versus none in the clopidogrel group. These data 
prompted the Food and Drug Administration Cardiovascular 
and Renal Drugs Advisory Committee to recommend avoiding 
using prasugrel close to surgical procedures. The relative risk 
of bleeding with prasugrel was higher in patients weighing 
less than 65 kg (HR 1.73, 95% CI: 1.07–2.79, P , 0.05) and 
patients 75 years of age or older (HR 1.35, 95% CI: 0.97–1.88, 
P = 0.078). The rates of hemorrhagic stroke were also remark-
ably higher in patients with a history of prior stroke or transient 
ischemic attack treated with prasugrel than with clopidogrel 
(6.5% versus 1.2%, P = 0.002).9
Given the abovementioned limitations of the second- 
and third-generation thienopyridines, there is an obvious 
clinical need to improve on the benefits observed with 
clopidogrel and prasugrel. The ever continuing development 
of pharmacotherapy for ACS is directed towards creating 
an antiplatelet agent that will overcome the limitations of 
the currently available thienopyridines, have a better safety 
profile, and have at least equivalent efficacy compared with 
the thienopyridines.
Ticagrelor
Chemical structure, pharmacodynamics, 
and pharmacokinetics
Ticagrelor (formerly AZD6140; AstraZeneca, Wilmington, 
DE) is the first oral agent in a new chemical class of 
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nonthienopyridine antiplatelet agents termed cyclopentyl-
triazolo-pyrimidines (Figure 5). Like the thienopyridines, 
ticagrelor blocks the platelet P2Y12 receptor to inhibit the 
prothrombotic effects of ADP.19 Ticagrelor binds revers-
ibly to P2Y12 without requiring metabolic activation. AR-
C124910XX is an active metabolite of ticagrelor, but the 
parent compound was shown to account for the majority of the 
antiplatelet effect.19,20 It needs only 1.5–3.0 hours to reach peak 
plasma levels, allowing a rapid antiplatelet effect. Ticagrelor’s 
half-life is approximately 12 hours and its antiplatelet effect 
is low at 48 hours after the last dose.19 In healthy volunteers, 
AZD6140 given as single oral doses of 100 mg to 400 mg had 
linear pharmacokinetics, nearly completely inhibited platelet 
aggregation two hours postdose, with a reduction of inhibition 
over the 24-hour postdose period, and was well tolerated.21
Clinical studies of ticagrelor
A randomized, double-blind, parallel-group study by Husted 
et al assessed the pharmacodynamics, pharmacokinetics, 
safety, and tolerability of ticagrelor with aspirin relative 
to that of clopidogrel in combination with aspirin in 200 
patients with stable atherosclerotic disease.20 The principal 
aim of the study was to compare the safety of four different 
doses of AZD6140 (50 mg, 100 mg, or 200 mg twice a day, 
and 400 mg once a day) with that of clopidogrel (75 mg 
once a day) in combination with aspirin (75 to 100 mg once 
a day) in order to choose the optimal dose to be further 
investigated in clinical trials. No loading dosages of the drugs 
were administered in this study. According to the results, 
AZD6140 at the doses of 100 mg twice a day, 200 mg twice 
a day, and 400 mg once a day were superior to AZD6140 at 
a dose of 50 mg twice a day and clopidogrel 75 mg once a 
day with regard to P2Y12-mediated platelet aggregation as 
measured by optical aggregometry both after initial dosing 
and at steady state. On day 1, the onset of peak inhibition of 
platelet aggregation occurred by two hours after AZD6140 
administration, while inhibition of platelet aggregation was 
minimal with clopidogrel. Remarkably, inhibition of   platelet 
aggregation with AZD6140 was reversible, as shown by 
the declining levels of inhibition of platelet aggregation at 
24 hours after the last dose. With regard to safety, AZD6140 
at the three higher doses was associated with more bleeding 
episodes than clopidogrel, although all but one bleeding event 
were qualified as minor. The sole major bleeding event was 
observed with AZD6140 400 mg once a day. Moreover, 
AZD6140 100 mg twice a day and 200 mg twice a day 
appeared to have a more favorable safety and tolerability 
profile than AZD6140 400 mg once a day with regard to 
frequency of dyspnea and ventricular pauses on Holter 
monitoring. Therefore, these two doses were selected for 
subsequent clinical evaluation.
The randomized, double-blind, double-dummy DISPERSE 
(Dose confIrmation Study assessing anti-Platelet Effects of 
AZD6140 versus clopidogRel in non-ST segment Elevation 
myocardial infarction)-2 trial further evaluated the safety, tol-
erability, and initial efficacy of either AZD6140 or clopidogrel 
added to aspirin in 990 patients with non-ST-segment eleva-
tion ACS.22 The patients were randomized in a 1:1:1 fashion 
to receive AZD6140 90 mg twice a day, AZD6140 180 mg 
twice a day, or a clopidogrel 300 mg loading dose plus 75 mg 
a day for up to 12 weeks. Patients in the AZD6140 group were 
further randomized to receive or not receive the 270 mg load-
ing dose of the drug. The primary endpoint, ie, Kaplan–Meier 
rate of protocol-defined major or minor bleeding over four 
weeks, did not differ between the three groups (9.8%, 8.0%, 
and 8.1%, respectively). Rates of major bleeding were also 
close (7.1%, 5.1%, and 6.9%, respectively). Notably, the 
bleeding rates were not different regardless of previous 
treatment with clopidogrel, or administration of a loading 
dose of AZD6140 or platelet glycoprotein IIb/IIIa inhibitors. 
Asymptomatic ventricular pauses longer than 2.5 sec were 
more common with AZD6140, particularly at 180 mg twice 
a day (5.5%, 9.9%, and 4.3%, respectively; P = 0.58 and 
P = 0.01, respectively, versus clopidogrel). Remarkably also, 
the study highlighted for the first time that among patients 
undergoing CABG 1–5 days after stopping the drug, treatment 
with AZD6140 as opposed to clopidogrel was associated with 
a numerically lower incidence of major bleeding, a finding 
consistent with the reversible inhibition of the P2Y12 receptor 
provided with AZD6140.
The ONSET/OFFSET study was a multicenter, random-
ized, double-blind, double-dummy, parallel-group study 
aimed at a comprehensive comparison of AZD6140 versus 
high-loading-dose clopidogrel antiplatelet onset and offset 
effect profile in 123 patients with stable coronary artery 
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disease.23 In this study, the patients treated with aspirin 
(75–100 mg a day) randomly received AZD6140 (a 180 mg 
loading dose and maintenance dose of 90 mg twice a day), 
clopidogrel (600 mg loading dose, 75 mg once a day main-
tenance dose), or placebo for six weeks. Inhibition of platelet 
aggregation was significantly (all P , 0.0001) more promi-
nent with AZD6140 than with high-loading dose clopidogrel 
at any study point (0.5, one, two, four, eight, and 24 hours 
after loading dose and at six weeks). The study also showed 
very rapid onset and fast offset of the antiplatelet effect of 
AZD6140 (Figure 6). Namely, at one hour after the loading 
dose, platelet inhibition provided by AZD6140 was approxi-
mately 1.6 times greater than the maximal platelet inhibition 
induced by clopidogrel that occurred only at eight hours 
after loading. Inhibition of platelet activity at 24 hours after 
the last dose was equivalent in AZD6140- and clopidogrel-
treated patients, while inhibition of platelet aggregation at 
48 hours after the last dose was numerically less at 48 hours 
and significantly less at 72 and 120 hours with AZD6140. 
Combined together, these data confirmed faster immediate 
offset of effect for AZD6140 relative to clopidogrel and 
further strengthened the observation from the DISPERSE-2 
trial that bleeding risk may be lower in patients undergoing 
surgery 48–120 hours after AZD6140 discontinuation.22
The RESPOND (Response to Ticagrelor in Clopidogrel 
Nonresponders and Responders and Effect of Switching 
Therapies) study was a randomized, double-blind, double-
dummy crossover trial that examined the use of ticagrelor 
in 98 patients with stable coronary artery disease as a func-
tion of responsiveness to clopidogrel.24 Nonresponsiveness 
to clopidogrel was defined as a #10% absolute change in 
20 µmol/L ADP-induced platelet aggregation between the 
baseline value and at 6–8 hours after the 300 mg clopidogrel 
loading dose. In a two-way crossover design, nonresponders 
and responders were randomly assigned to receive clopi-
dogrel (600 mg loading dose then 75 mg once daily) or 
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ticagrelor (180 mg loading dose then 90 mg twice daily) for 
14 days (period 1). Thereafter, all nonresponders switched 
treatment, with half of the responders continuing the previous 
treatment, and half switching treatment. The use of ticagrelor 
among nonresponders resulted in a .10%, .30%, and .50% 
decrease in platelet aggregation from baseline in 100%, 75%, 
and 13% of patients, respectively. In addition, there was a 
significant (P , 0.0001) decrease in platelet aggregation from 
a mean 59% to 35% in patients switched from clopidogrel to 
ticagrelor and an increase in platelet aggregation from mean 
36% to 56% in patients switched from ticagrelor to clopidogrel. 
These results indicated that the antiplatelet effect of ticagrelor 
is consistent regardless of responsiveness to clopidogrel, that 
ticagrelor may represent a logical substitute for clopidogrel 
nonresponders, and that platelet inhibition in patients respon-
sive to clopidogrel may be significantly augmented by switch-
ing to ticagrelor without reduction in antiplatelet effect.
Platelet Inhibition and Patient  
Outcomes trial
PLATO (Platelet Inhibition and Patient Outcomes) was a mul-
ticenter, double-blind, double-dummy, randomized Phase III 
trial conducted at 862 centers in 43 countries comparing 
ticagrelor (180 mg loading dose then 90 mg twice a day 
thereafter) and clopidogrel (300 to 600 mg loading dose then 
75 mg a day thereafter) for the prevention of cardiovascular 
events in 18,624 patients with ACS (Figure 7).25,26 The primary 
efficacy endpoint was time to the first occurrence of death 
from vascular causes, MI, or stroke. The principal secondary 
efficacy endpoint was the primary efficacy endpoint examined 
in the subgroup of patients triaged to invasive management.
Ticagrelor demonstrated superiority to clopidogrel 
in reducing rates of the primary endpoint of death from 
cardiovascular causes, MI, or stroke at 12 months (9.8% 
versus 11.7%, P , 0.001, Figure 8). A significant difference 
in rates of the primary endpoint was observed at 30-day 
follow-up which persisted at one year (Figures 9A and 9B). 
Remarkably, there was also a significant reduction in the 
rate of individual endpoints with ticagrelor, including all-
cause death (4.5% versus 5.9%, P , 0.001), cardiovascular 
death (4.0% versus 5.1%, P = 0.001), and MI (5.8% versus 
6.9%, P = 0.005). By subgroup analysis, the results in favor 
of ticagrelor were consistent in the 33 subgroups, with the 
exception of patients weighing less than the median weight 
for their gender, patients not taking lipid-lowering drugs at 
randomization, and patients enrolled in North America.26 
Patients in North America had nonsignificantly higher 
rates for the primary endpoint when treated with ticagre-
PLATO study design
Primary endpoint: 
Key secondary:    
• Total mortality + MI + Stroke 
• CV death + MI + Stroke + recurrent ischemia + TIA + arterial thrombotic events
• MI alone / CV death alone / Stroke alone / Total mortality
Primary safety:     
6–12-month exposure
Clopidogrel
If pretreated, no additional loading dose;
if naive, standard 300 mg loading dose,
then 75 mg qd maintenance;
(additional 300 mg allowed pre PCI)
Ticagrelor
180 mg loading dose, then
90 mg bid maintenance;
(additional 90 mg pre-PCI)
UA/NSTEMI (moderate-to-high risk) STEMI (if primary PCI)
All receiving ASA; clopidogrel-treated or-naive;
randomized within 24 hours of index event
(N = 18,624)
• CV death + MI + Stroke
• CV death + MI + Stroke  in patients intended for invasive management 
• Total major bleeding
Figure 7 The Platelet Inhibition and Patient Outcomes study algorithm. 
Abbreviation: PLATO, platelet inhibition and patient outcomes. 
Abbreviations: UA, unstable angina; PCI, percutaneous coronary intervention; ASA, acetylsalicylic acid; CV, cardiovascular; TIA, transient ischemic attack.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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lor than those treated with clopidogrel (HR 1.25, 95% CI: 
0.93–1.67). The reasons for the diverse outcomes in differ-
ent geographic regions are not known, and might be related 
but not limited to the differences in demographics, patient 
compliance, and standards of ACS care. Higher dosages of 
aspirin were used in the North American population than in 
the rest of the study population. Further research is needed 
to clarify whether there are region-specific differences in 
outcomes for ACS patients treated with ticagrelor versus 
aspirin.
The incidence of protocol-defined major bleeding was 
almost identical between ticagrelor and clopidogrel (11.6% 
versus 11.2%, respectively, P = 0.43, Figures 10 and 11). 
The same was true with regard to the incidence of major 
TIMI (Thrombolysis in Myocardial Infarction) bleeding, or 
fatal or life threatening bleeding (Figure 11). In subgroup 
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Figure 8 Kaplan–Meier estimate of time to first primary efficacy event (composite of cardiovascular death, myocardial infarction, or stroke) in PLATO trial. 
Abbreviation: PLATO, platelet inhibition and patient outcomes.
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analysis, the absence of a significant difference in rate of 
major bleeding was consistent among all the studied sub-
groups, apart from body mass index (P = 0.05 for interaction). 
Rates of CABG-related major bleeding or bleeding requiring 
transfusion were also similar between the two groups. 
However, in the ticagrelor group, there was a higher rate of 
non-CABG-related major bleeding according to the study 
criteria (4.5% versus 3.8%, P = 0.03) and TIMI criteria 
(2.8% versus 2.2%, P = 0.03). With ticagrelor as compared 
with clopidogrel, there were more episodes of intracranial 
bleeding (26 [0.3%] versus 14 [0.2%], P = 0.06), including 
fatal intracranial bleeding (11 [0.1%] versus one [0.01%], 
Type of bleeding Definition
Major bleeding (life threatening) 
Fatal or intracranial or intrapericardial with 
cardiac tamponade or hypovolemic shock or 
severe hypotension requiring vasopressors or 
surgery or bleeding with associated drop in 
hemoglobin of >50 g/L (3.1 mmol/L) or 
blood/packed red blood cells transfusion ≥4
units.
Major bleeding – other
Significantly disabling (eg, intraocular with 
permanent vision loss); Associated drop in 
hemoglobin of 30-50 g/L (1.9–3.1 mmol/L); 
Transfusion of 2–3 units
Minor bleeding  Requires medical intervention to stop or treat 
bleeding
Minimal bleeding All others not requiring intervention or treatment
Figure 10 Definitions of bleeding in the PLATO trial. 
Abbreviation: PLATO, platelet inhibition and patient outcomes.
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P = 0.02) but fewer episodes of other types of fatal bleeding 
(9 [0.1%], versus 21 [0.3%]; P = 0.03).26
The following adverse effects were more commonly 
associated with ticagrelor in the PLATO trial. Patients treated 
with ticagrelor experienced dyspnea significantly more often 
than those treated with clopidogrel (13.8% versus 7.8%, 
respectively, P , 0.001), albeit this rarely resulted in study 
drug discontinuation (0.9% in the ticagrelor group versus 
0.1% in the clopidogrel group).
There was also a higher incidence of ventricular pauses 
$three seconds in duration by Holter monitoring during the first 
week of treatment in the ticagrelor group (5.8% versus 3.6%, 
P = 0.01) but this did not translate into a higher incidence of 
syncope (1.1% versus 0.8%, P = 0.08) or pacemaker insertion 
(0.9% in both groups, P = 0.87). Although the exact reasons 
for more frequent episodes of dyspnea and ventricular pauses 
with ticagrelor are not known, the most plausible mechanism 
is related to the structural similarity of ticagrelor to adenosine 
and possibly altered reuptake of adenosine by red blood cells. 
Finally, patients treated with ticagrelor as opposed to clopi-
dogrel had a more pronounced increase in serum creatinine and 
uric acid at one month and at one year, although the differences 
did not exist after one month of drug discontinuation. 26
Ticagrelor in patients with a planned 
invasive strategy
A total of 13,408 patients, comprising 72% of the entire PLATO 
population with ACS, were planned by the site investigators 
at the time of randomization to be managed with an invasive 
approach, including early coronary angiography with subsequent 
revascularization (PCI or CABG), when appropriate.27 
Approximately half of the patients had had a STEMI. A total 
of 11080 patients were triaged to revascularization, including 
10,298 patients who were triaged to PCI and 782 patients who 
were triaged to CABG. Median time to PCI was 2.4 hours 
(interquartile range 0.8–20) post randomization in patients with 
non-STEMI or unstable angina, and 0.5 hours (interquartile 
range 0.2–1.0) in patients with STEMI, and median time to 
CABG was six days (interquartile range 3–10).
The results in patients managed with an invasive strategy 
in fact repeated the results in the entire PLATO population. 
Ticagrelor was superior to clopidogrel in terms of reduction of 
the primary composite endpoint (cardiovascular death, MI, or 
stroke, Figure 12) and secondary endpoints of cardiovascular 
mortality and MI (Figures 13A and 13B). All-cause mortality 
rate was also significantly reduced with ticagrelor (3.9% versus 
5.0%, P = 0.03). The benefit of ticagrelor versus clopidogrel 
for the primary endpoint was similar across a wide range of 
subgroups, irrespective of the loading dose of clopidogrel and 
the use of platelet glycoprotein IIb/IIIa inhibitors.
Among patients triaged to PCI, ticagrelor was associated 
with significantly reduced rates of definite stent thrombosis 
(1.3% versus 2.0%, P = 0.005), including patients treated 
with drug-eluting stents (1.3% versus 1.8%, P = 0.23) and 
bare-metal stents (1.4% versus 2.1%, P = 0.012). Rates of 
definite stent thrombosis were lower with ticagrelor, regard-
less of whether the patients received a clopidogrel loading 
dose of 600 mg or less.
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The rates of PLATO-defined total major bleeding (11.5% 
in the ticagrelor group versus 11.6%, P = 0.88), fatal or life-
threatening bleeding (6.0% versus 5.9%, P = 0.61), or other 
major bleeding (5.9% versus 6.2%, P = 0.40), as well as major 
TIMI bleeding (7.9% versus 7.9%, P = 1.0), severe GUSTO 
bleeding (2.9% versus 3.2%, P = 0.38), or transfusion of 
whole blood/packed red blood cells (8.9% versus 8.7%, 
P = 0.91) or platelets (1.6% versus 1.9%, P = 0.25) did not 
differ between the two groups. The rates of major non-CABG 
bleeding by PLATO definition were not significantly higher 
(4.7% versus 4.0%, P = 0.10) and those of CABG-related 
bleeding were not significantly lower (7.1% versus 8.0%, 
P = 0.07) with ticagrelor.
In the subgroup analysis from the PLATO trial of 8430 
patients with STEMI undergoing primary PCI, treatment with 
ticagrelor as opposed to clopidogrel resulted in lower rates 
of cardiovascular death, MI, or stroke (9.3% versus 11.0%, 
P = 0.02).28 There was also a significant reduction in all-cause 
death (4.9% versus 6.0%, P = 0.04), MI (4.7% versus 6.1%, 
P = 0.01), and definite stent thrombosis (1.6% versus 2.5%, 
P = 0.01) with ticagrelor compared with clopidogrel, without 
differences in rates of major bleeding between the two drugs 
(9.0% versus 9.3%, P = 0.63).
Dyspnea in patients treated  
with ticagrelor
Prespecified prospective analysis from the ONSET/OFFSET 
trial provided comprehensive assessment of cardiac and pulmo-
nary function at baseline and at six-week follow-up in patients 
treated with ticagrelor as compared with clopidogrel.29 The 
8
6
4
2
0
8
6
4
2
0
Number at risk
Clopidogrel
Ticagrelor
Time after randomization (days)
Clopidogrel Ticagrelor A       Myocardial infarction
B         Cardiovascular death
C
u
m
u
l
a
t
i
v
e
 
i
n
c
i
d
e
n
c
e
 
(
%
)
C
u
m
u
l
a
t
i
v
e
 
i
n
c
i
d
e
n
c
e
 
(
%
)
5.26
6.59
3.44
4.33
2987 3706 4849 5917 6062 6157 6676
3078 3766 4924 6010 6173 6268 6732
Number at risk
Clopidogrel
Ticagrelor
3164 3917 5114 6209 6332 6376 6676
5141 3591 3233 6241 6375 6439 6732
240 300 360 180 120 60 0
Figure 13 Cumulative Kaplan–Meier estimates of time to myocardial infarction A or cardiovascular death B in patients triaged to an invasive strategy. Copyright © 
2010. Adapted with permission from Cannon CP, Harrington RA, James S, et al; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with 
clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283-293.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
975
Ticagrelor in acute coronary syndrome
analyzed data included echocardiographic assessment of left 
ventricular ejection fraction, N-terminal pro-brain natriuretic 
peptide and pulmonary function parameters, including forced 
expiratory volume in one second (FEV1), forced volume vital 
capacity (FVC), FEV1/FVC, mean forced expiratory flow 
between 25% and 75% of the FVC, lung volume, total lung 
capacity, residual volume, minute ventilation, tidal volume, 
respiratory rate, single-breath diffusing capacity of lung 
for carbon monoxide, and oxygen saturation. At six weeks, 
dyspnea was experienced by significantly (P , 0.0001) more 
patients treated with ticagrelor (38.6%) as compared with 
clopidogrel (9.3%) or placebo (8.3%). The majority of cases 
of dyspnea, as assessed by the site investigators, were mild 
defined as awareness of sign or symptom but easily tolerated, 
and only three patients experienced moderate dyspnea, defined 
as discomfort sufficient to cause interference with normal 
activities. In the majority of patients in the ticagrelor group 
(17 of 22), dyspnea developed within one week, including 
eight patients in whom dyspnea occurred within the first 
24 hours of treatment. Dyspnea persisted up to the end of six 
weeks in only three patients with dyspnea in the ticagrelor 
group. There were no significant changes in any of the car-
diac or pulmonary parameters in any of the groups between 
baseline and six-week follow-up assessments. There was also 
no significant difference in the percent change from baseline 
to six-week follow-up for all the cardiac and pulmonary 
measurements between the treatment groups.29
Conclusion and future directions
In the pivotal clinical trials, ticagrelor, a new potent oral 
direct-acting P2Y12 inhibitor, demonstrated substantial benefits 
against clopidogrel, and thus providing a new solution in the 
care of patients with ACS. Ticagrelor is well tolerated, and has 
faster and greater platelet inhibition than clopidogrel, making 
this new agent especially advantageous in the setting of urgent 
PCI when immediate platelet inhibition is of particular impor-
tance. Reversibility is another essential feature of ticagrelor, 
allowing usage of this agent in certain clinical scenarios, 
including surgery, in which recovery of platelet function is 
necessary sooner than the 5–7 days required for clopidogrel. 
The antiplatelet impact of ticagrelor is to a great extent not 
dependent on clopidogrel response status, thus overcoming 
the issue of clopidogrel unresponsiveness. The prospective, 
randomized PLATO trial has established the clinical utility of 
ticagrelor in a wide range of patients with ACS managed with 
contemporary antithrombotic therapies and invasive strategies 
when indicated. Ticagrelor was proven to be superior to clopi-
dogrel in reduction of the composite endpoint of cardiovascular 
death, MI, or stroke, and resulted in enhanced survival without 
an increase in overall major bleeding.
The mechanisms of how ticagrelor affected survival are not 
known. First, this may be by chance alone. However, a highly 
significant difference in mortality rates between the ticagrelor 
and clopidogrel arms makes this explanation unlikely. Second, 
survival benefit in favor of ticagrelor may be related to the 
PLATO trial design, in which patients were randomized early 
from onset of ischemic symptoms (within 24 hours) relative 
to TRITON-TIMI 38 trial (within 72 hours); the beneficial 
effect of ticagrelor versus clopidogrel may be more prominent 
with earlier initiation of antiplatelet therapy. Third, given that 
ticagrelor prevents adenosine reuptake by red blood cells, it may 
potentially improve microcirculatory flow and reduce the size 
of infarction. In a randomized, double-blind, placebo-controlled 
multicenter trial of adenosine as an adjunct to reperfusion in 
the treatment of acute myocardial infarction (AMISTAD-II), a 
70 µg/kg/min adenosine infusion correlated with smaller infarct 
size and fewer clinical events. And last, but not least, enhanced 
survival with ticagrelor may be related to reduction in rates 
of MI without increasing bleeding complications, providing 
further support for the bleeding-ischemia hypothesis raised 
in previous ACS trials, in which reduction in mortality was 
parallel to the decrease in major bleeding. 30,31
The development and clinical introduction of ticagrelor 
is believed to be changing the standard of care for ACS.32 
However, further investigation is needed to optimize the 
antiplatelet strategy to meet the needs of the individual patient 
with ACS. The twice-daily dosing is a drawback of ticagrelor 
that may potentially adversely affect patient compliance, and 
requires further careful studies. Patients with multiple risk 
factors for bleeding events may not benefit from ticagrelor 
similarly to prasugrel. A higher incidence of hemorrhagic 
stroke and gastrointestinal bleeding with ticagrelor com-
pared with clopidogrel is certainly a concern, even if the 
numbers of events were low in the PLATO trial. There 
are no data on whether ticagrelor may be used in patients 
undergoing elective PCI or in combination with fibrinolytic 
agents. At this time it is also not clear if ticagrelor may be 
used safely in patients with chronic obstructive pulmonary 
disease, conduction system abnormalities, hyperuricemia, or 
chronic kidney disease, all of which warrant further indepth 
analysis. More studies are also necessary to clarify whether 
there are true geographic differences in outcomes between 
patients treated with ticagrelor versus clopidogrel.
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